Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study
For Members , below, I will walk through the labs and tests you should consider before starting, what metabolic changes to expect in the first 8-12 weeks (and why they matter more than the scale), how to structure your protein and training to protect muscle while everyone else is losing it, when dose escalation actually makes sense, the monitoring schedule that separates success from failure, and the warning signs that tell you when to adjust
A growing number of patients are now seeking medically supervised care not only for what they lose, but for what they want to preserve
About this article Cite this article Jones, O.T., Ranmuthu, C.K.I., Hall, P.N